It has been recognized that overexpressed-HER2 leads to increased proliferation, angiogenesis, and reduced apoptosis occurring in various cancers: breast cancer [25–27], GC [28], ovarian cancer [29], salivary gland carcinoma [30], colon [31], bladder [32], lung [33], and esophagus [34]. This evidence concerns the gene ERBB2 and gastric cancer.